Mazie Tsang, M.D.

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

The purpose of this study is to assess the feasibility of automated delivery of a geriatric assessment form to patients and providers in an outpatient setting, measured by patient form completion rates and provider access before the visit. To evaluate patient and provider satisfaction with the automated GA delivery process. To identify barriers and facilitators to implementation based on survey feedback. To assess the impact of the Practical Geriatric Assessment on rates of grade 3-5 adverse events from cancer-directed therapy.

The purpose of this study is to compare the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

The purose of this study is to evaluate the effiectiveness, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory Primary Central Nervous System Lymphoma PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolimide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B). Mayo Clinic is only participatin gin Part B, and only in the MTR regimen. 

The purpose of this study is to identify factors important to decision-making for older adults with indolent lymphomas and to identify minimum clinically significant differences in QOL domains are important to older patients in their decision-making about clinical management.  And to characterize longitudinal health-related quality of life (QOL) for older adults with indolent lymphomas.

The purpose of this research is to understand how people with lymphoma make decisions about treatment and why. Study participation involves partaking in one virtual focus group session with a group of up to 8 people with lymphoma and up to two group moderators. Participants will be asked questions about what they prefer in a lymphoma treatment and how they have made decisions on treatment of their lymphoma in the past. Questions may be about past experiences as well as future hypothetical situations. We hope that what we learn from these discussions will help us to improve care for people with lymphoma by improving how we decide on treatments.